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ABSTRACT 
Despite advances in pharmacological research providing means for individually customized patient 
attribute treatments, the 'one-size-fits-all' paradigm remains. Customization is associated with cost 
increases and the value assessment of customized medicinal products shows upon a narrow economic 
focus. Inspired by value models, emerging in manufacturing industry research, this study suggests a 
novel methodology encompassing a full sustainability perspective, including the social, economic and 
ecological dimension, for design decision support for medicinal products. A concept screening matrix 
is adapted, using sustainability criteria as value indicators. The focus is to create value for the whole 
pharmaceutical value chain whilst keeping the core purpose of medicinal products, i.e. to bring societal 
benefits. An illustrative case study presents an application of the methodology on a commercial product 
for curing hypertension. The traditional product design for hypertension treatment is compared to a 
customized product design. Results indicate that a customized product design is preferable if value is to 
be created from a social or/and an ecological sustainability perspective. 
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1 INTRODUCTION 
Advances in pharmacological research have provided opportunities for individually customized patient 
attribute treatments. These attributes can be categorized as biological, behavioural and environmental 
attributes (Crommelin et al., 2011). The current ‘one-size-fits-all’ paradigm in medicine production is 
challenged. Several attempts have had the ambition of redesigning the medicinal product to improve the 
customizability. For example, Siiskonen et al. (2018) developed a modularized product concept of oral 
dosage forms (ODF), more specifically a tablet. These modules provide different functionalities of the 
product to comply with the patients’ attributes. 
However, customization of medicinal products is commonly associated with various cost increases 
compared to traditional medicinal products due to e.g. new manufacturing technology investments as 
modularized tablet design requires additional assembly processes to provide an administrable product. 
Additionally, customization induces an increase in the number of stock-keeping units (SKU), leading to 
increased complexity in production and distribution - associated with increased cost (Lee et al., 2015). 
Research regarding cost-efficient customized treatments, such as that of Hatz et al. (2014) and Srai et al. 
(2015), shows a narrow focus not only being limited to an economic assessment of treatments, 
overshadowing the core purpose of medicinal products, i.e. treating people, but also a focus on the 
consequences of a specific phase of the pharmaceutical value chain. More focus is needed on finding 
medicinal product designs complying with this core purpose and in the end providing value for the whole 
value chain, for example by conducting a proper cost-benefit analysis. 
Research on value-based decision support has emerged in the manufacturing industry, e.g. the aerospace 
industry, where a full sustainability perspective, i.e. including a social, economic and ecological dimension, 
has been adopted when assessing new products (Bertoni et al., 2015; Hallstedt et al., 2015). These value 
models result in a Net Present Value analysis and thus, require translation of criteria into monetary metrics. 
The concept screening matrix by Ulrich and Eppinger (2012), based on the concept selection method by 
Pugh (1990), is another value modelling approach where conceptual designs are comparatively related 
against a reference design, i.e. a translation into costs is not necessary. 
To our best knowledge, no studies on product designs and the consequences for the pharmaceutical value 
chains, from a full sustainability perspective, have been conducted. Thus, inspired by above-mentioned 
value models, the aim of this research is to address this gap by proposing a novel methodology to support 
decisions for re-designed medicinal products, more specifically ODF, which is the most common dosage 
form today (Nagashree, 2015). The ODF is re-designed to embrace a higher level of customization than 
traditional product designs and the consequences for the value chain are assessed from a full sustainability 
perspective. The focus is to create value for the pharmaceutical value chain whilst bringing societal 
benefits. The study adopts the value assessment approach by Ulrich and Eppinger (2012), i.e. concepts are 
related benefit-wise to a reference concept with respect to chosen criteria. Thus, a concept screening matrix 
is adapted, allowing the assessment of product concepts using sustainability criteria as value indicators. The 
research question is ‘How is the value chain affected from a sustainability perspective due to an 
introduction of customized product design?’ An illustrative case study is performed to test the methodology 
on a commercial product for hypertension treatment. The traditional product design is compared to a 
customizable product design. The theoretical contribution of this study is a methodology to develop and 
assess new medicinal product designs, integrating a full sustainability value perspective. The practical 
contribution is a proposal for how to design a medicinal product to increase product value. The remaining 
paper is organized as follows: Section 2 outlines the research approach and Section 3 presents the novel 
methodology. Section 4 describes an illustrative case study to present the application of the methodology. 
The results from the illustrative case study are presented in Section 5 and discussed in Section 6 jointly 
with a discussion of the developed methodology. Section 7 concludes the paper and describes future work.  
2 RESEARCH APPROACH 
A sequence of research activities was conducted to address the perceived research gap. First, theory 
developing studies were conducted to develop a methodology for decision support. These studies included 
the adoption of a previous study by Siiskonen et al. (2018) to establish a customized product concept 
(CPC). A qualitative sustainability assessment tool, SLCA2.0 (Villamil et al., 2018), was chosen to 
estimate sustainability performance of such an ea phase design, from a full sustainability perspective. The 
sustainability performance of the traditional product concept (TPC) was benchmarked in parallel with the 
868
ICED19  
aid of established literature and expert knowledge, i.e. researchers in value-driven design and sustainable 
product development, informed by literature and an expert with detailed knowledge about the industrial 
case. From literature studies, the value chain of a pharmaceutical product (Aitken, 2016) and the variables 
prone to be affected due to a change in product design were clarified. Finally, the concept screening matrix 
by Ulrich and Eppinger (2012) was adapted to enable simulations providing quantitative data on a value 
comparison of CPC to TPC. Secondly, an illustrative case study was performed to illustrate the application 
of the developed methodology. A commercial product for curing hypertension was chosen for the 
illustrative case study. 
3 PROPOSED METHODOLOGY  
To make a value assessment of medicinal products from a sustainability perspective, a methodology is 
presented in this section. Figure 1 outlines the proposed methodology composed of various parallel and 
interconnected activities and a description of the activities is provided in the succeeding sections. Section 
3.1 describes a sustainability assessment of medicinal products, adaption and execution of the product 
platform of CPC and describing and qualitatively comparing the TPC and the CPC according to 
sustainability performance variables (SPVs). Information from the qualitative comparison is used for 
consequence analysis on the value chain of pharmaceutical products, which is described in Section 3.2. The 
value chain assessment is quantified into a value model in Section 3.3 to calculate the relative value of the 
CPC to the TPC. 
3.1 Sustainability lifecycle assessment of medicinal products 
A sustainability assessment is conducted using SLCA2.0 (Villamil et al., 2018). The sustainability  
performance of respective product design, the CPC and TPC, is qualitatively assessed from a full 
sustainability perspective. SLCA2.0 applies backcasting from eight sustainability principles (SPs), 
corresponding to anthropogenic mechanisms of ecological- (SP 1-3) and social system destruction (SP 4-
8), which are described in detail in the Framework for Strategic Sustainable Development (Broman and 
Robért, 2017). In this study, a comparative SLCA (Villamil et al., 2018) is conducted, following the 
general guidelines for a comparative LCA as described in ISO 14001.  The two final steps of SLCA2.0 are 
followed with the aim to qualitatively compare the CPC with the TPC. Templates and guiding questions, 
summarized in Figure 2, inform each step and this information is complemented by additional literature as 
well as expert knowledge since this is the first application of the method on a medicinal product. The SPs 
translate into SPVs and are used to describe the CPC and the TPC. The SPVs originates from the guiding 
questions shown in Figure 2. The relevant set of questions are chosen by the researchers according to topics 
found in previous literature conducting sustainability assessments of medicinal products, such as Slater 
et al. (2007) and Sheldon (2016). Since the literature shows upon a narrow focus on the ecological 
sustainability dimension, the researchers chose additional questions according to their best judgment. The 
guiding questions for this study are shown in bold in Figure 2. 
Figure 1. The proposed methodology to support design decisions of medicinal products 
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Figure 2. Adopted guiding questions per sustainability dimension (Villamil et al., 2018). 
To enable a comparison of the CPC to the TPC, the SPVs need to be transformable into measurable units. 
SPVs can be of both quantitative, e.g. material consumption and number of SKUs, as well as of qualitative 
nature, e.g. usage and end-of-life fate. 
3.1.1 Product platform development and execution 
To describe a CPC according to SPVs, a customized product design is established adopting an approach 
developed by Siiskonen et al. (2018). Based on the Configurable Component (CC) framework (Claesson, 
2006), this platform approach builds on functional modelling to structure the product according to its 
functional requirements (FR). The FRs are established from a translation of patient attributes to various 
design parameters. Design solutions (DSs) are provided to FRs, and these are encapsulated as 
independently functioning configurable components (CC). Constraints (Cs) are used for potential 
restrictions of functional regions. This model forms the product architecture, i.e. the product platform 
foundation.  
The platform modelling software CCM (Claesson, 2006) is used for modelling and execution of the 
product platform, generating sets of product variants grounded in the product architecture of CPC. Note 
that CPC is a concept grounded in one product architecture but due to scalable properties of the CC-objects, 
sets of product variants can be established. The CCM software is limited to solving a full factorial 
combinatorial problem and has no inherent function to eliminate unfeasible solutions. Thus, sets of 
configured product variants are imported into MATLAB to eliminate unfeasible solutions and to quantify 
the SPVs of the CPC. 
3.2 Value chain impact analysis 
To assess the overall value created from introducing a CPC, the value chain of a pharmaceutical product is 
studied with the aim of identifying which phases, the variables of these phases, and how the value of these 
variables would be affected. The effects are studied by analysing the SLCA2.0 results and complemented 
by manufacturing performance-related information by Srai et al. (2015) and Harrington et al. (2017). The 
variables are called value driving impact variables (VDIV) and are categorised according to the 
sustainability dimension (SD) affected.  The value change is stated for each variable. 
Figure 3 presents an illustration of the pharmaceutical value chain by Aitken (2016). The value chain is 
assumed to remain in the current paradigm, but a customized product design is introduced into it. The 
pharmaceutical value chain consists of three phases, manufacturing of the medicinal product, delivery to 
dispensing point and dispensing to end user. The manufacturing phase includes activities from research and 
development to regulatory approval and commercial production (Food and Drug Administration, 2018). 
Commercial production of medications is divided into primary production, where the raw material for the 
medication is produced, and into secondary production, the phase during which the final medicinal product 
is produced. The purpose is to connect product design with manufacturing performance and to succeeding 
phases i.e. delivery to dispensing point and dispensing to end user and studying the propagation of 
consequences due to a change in product design. Thus, initial research and regulatory considerations are 
outside scope. Additionally, the raw material produced, primary production, is assumed to remain static and 
hence be independent of product design. 
 
Figure 3. Traditional pharmaceutical value chain adopted from Aitken (2016). 
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3.3 Value modelling 
Value modelling is employed for systematic product design decisions. A value function is developed 
adapting the concept screening matrix by Ulrich and Eppinger (2012). This matrix will provide a 
quantitative number of the relative value of the CPC compared to TPC. The aim is to find the most value-
creating product design. The resulting value function is presented in Equation (1). 
 
 social ecological economic
social ecological economic
vdiv vdiv vdiv
U w w w
i j k
 (1) 
U is the relative value of the CPC compared to the TPC. The respective w’s are weights of each 
sustainability dimension and are varied to emphasise various preferences. For example, if a product concept 
performing well from a social sustainability perspective is desired, the weight of this dimension is given a 
higher quantity. The respective vdiv ’s describe the value change of VDIVs. The vdiv ’s for each 
sustainability dimension are summarized and normalized with respect to the number of VDIVs, i , j  and k
, that each dimension embed.  
4 ILLUSTRATIVE CASE STUDY 
A commercial medicinal product is used to test the proposed methodology described throughout Section 3. 
This product is aimed at curing hypertension. Unmanaged hypertension can lead to heart attack and stroke 
(MacGill, 2018). The product chosen adopts the dosage form of a tablet. The TPC follows the subsequent 
assumptions; the product design embraces a fully monolithic, i.e. integral product design and embeds a 
single active pharmaceutical ingredient (API). The function of an API is to provide a therapeutic effect in 
the body. The API density is 1.4 kg/mm3. The treatment today is offered in three variants and is described 
according to API content, 2.5, 5 and 10 mg. These product variants have a flat-faced cylinder shape with a 
diameter of 8 mm and height of 2.5 mm; hence, the resulting volume of each variant becomes 126 mm3. 
Additionally, the tablet embeds excipients, lactose and hydroxypropyl methylcellulose (hypromellose), in 
the 20:80 ratio, and provide the tablet with functions to provide material and modifying the release of API, 
respectively. 
The CPC is assumed to embrace a modularized tablet design consisting of two different types of modules. 
The function of the first module type is to provide a therapeutic effect and embeds 0.1 mg API. The API is 
the same as for the TPC. The drug loading of the modules is 30% and the remainder is assumed to consist 
of excipients, the same as in the TPC. The second module has a function to provide material and modify 
the release of API and contains 10 mg excipients. The geometrical volumes of the product variants of CPC 
range from 4 mm3, the size of a preferred medication for children assuming a tablet height of 1 mm3 
(Klingmann et al., 2013), to 126 mm3, i.e. the volume of the TPC. 
The treatment of the patient population is assumed to follow a normal distribution. The dosage need 
covers the interval from 2.5 to 10 mg, and 99.7% of the treatment need is assumed to fall inside 2.5 and 
10 mg. The patient population is generated by using a normal random number generator in MATLAB. 
One thousand simulations were performed to provide an average population. The treatment of the 
population with TPC is assumed to be performed in a surplus manner to ensure sufficient dosage; 
patients requiring a dose i) of 2.5 mg or less are offered a product variant of size 2.5 mg, ii) larger than 
2.5 mg but less than or equal to 5 mg are offered a product variant of 5 mg, iii) larger than 5 mg are 
offered a product variant of 10 mg. 
The treatment of the population with the CPC is performed by offering a dose between 2.5 and 10 mg, with 
a dose step of 0.1 mg (the size of API module). The number of filling modules in each product variant of 
the CPC follows the assumption; for each dose step that a product variant is configured, product variants 
exist that are equal with regard to dose but different with regard to the number of filling modules. These 
product variants, equal in dose content, cover the whole range of product variants when the number of 
filling modules is varied (inside the allowed product volume region). These variants for respective dosages 
are assumed to be configured in equal quantities. 
The relative value of the CPC compared to TPC is assessed in simulations, where various scenarios, see 
Table 1, undertake different values on respective   in Equation (1). The respective     ’s of the CPC are 
quantified in the following manner: if the value of a VDIV is increased when introducing the CPC the      
is set to +1 and if the value decreases the      is set to -1, an unchanged value is quantified as 0. 
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Table 1. Scenarios prepared to assess the relative value of the CPC. 
Scenario 1 2 3 4 5 6 
socialw  
0.67 0.67 0 0.33 0.33 0 
ecologicalw  
0.33 0 0.67 0.67 0 0.33 
economicw  
0 0.33 0.33 0 0.67 0.67 
5 RESULTS FROM THE ILLUSTRATIVE CASE STUDY 
This section presents the results from the illustrative case study described in Section 4. 
5.1 Sustainability performance assessment of a customized product design 
Figure 4 shows the architecture of a customized product design for hypertension treatment. The physical 
realization of the product is a modularized tablet design. The FR on the highest hierarchical level is provide 
treatment and realized through the DS tablet. The DS tablet is constrained by size, more specifically 
volume. The tablet is further expressed in sub-FRs that the tablet embeds, treat disease, provide suitable 
size and provide sustained release. Note that the FRs provide suitable size and provide sustained release 
are conceptually realized as a common DS, filling modules, hence the physical realization of these FRs are 
in the same modules. 
The DS API module to the FR treat disease is scalable regarding the number of modules in a product 
variant. Thus, the platform execution generates a set of product variants consisting of various numbers of 
modules. These product variants cover each dosage in-between 2.5 and 10 mg, with a dose step of 0.1 mg. 
Likewise, the DS filling modules is scalable according to the number of modules. Varying the number of 
filling modules provides different sizes of tablets to facilitate administration, which is a known difficulty 
(Food and Drug Administration, 2015). Additionally, opportunities to tamper with the tablets release 
properties arise, which are dependent on the size and shape of a tablet (Goyanes 
et al., 2015). How the release rate is affected is outside the scope of this study. 
5.1.1 Sustainability performance variables 
The execution of the product platform results in measurable SPVs for the CPC. These SPVs are listed in 
Table 2. Likewise, the SPVs of the TPC have been listed for comparison and follows the assumptions 
presented in Section 4. As mentioned, the TPC is offered in three variants and an average amount of 
material consumption is presented. The CPC platform provides 76 feasible product variants by platform 
execution inside the feasible volume range 4 to 126 mm3. These product variants are described in the 
number of modules and module sizes, hence the material consumption of variants is calculated from this 
data. The average material consumption of the whole set is used to enable comparisons. 
Product design change is the focus of study, hence succeeding life-cycle phases are adopting the nature of 
the current paradigm. Changes to succeeding phases are logically concluded. For example, an additional 
assembly process is required to configure an administrable product from modules, the usage of a 
customised dosage of API is assumed thus, minimizing leftovers during end-of-life and no changes occur 
to package recycling. 
 
 
 
 
 
 
 
 
Figure 4. The architecture of the CPC. Adapted from Siiskonen et al. (2018). 
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Table 2. SPVs, derived from the SLCA, for the TPC and a CPC. 
SPV TPC  CPC 
Design: Nature of 
design and 
dimensions 
Monolithic design with form of a cylinder 
with flat faces, h = 2,5 mm; p= 8 mm; 
V = 126 mm3  
Modularized design with various forms; 
Various sizes; Volume range = [4,126] mm3 
Raw material: 
amount, absolute, 
average[mg/unit] 
API: 2.5; 5; 10 -  
Excipients: 175.4; 172.9; 167.8 
Average: API: 8.2 - Excipients: 169.6 
API: 2.5 to 10 - Excipients: Varying amounts, 
scalable property 
Average: API: 6.2 - Excipients: 90.7 
Manufacturing: 
Technologies 
Traditional dry powder mixing and 
compressing in a batch process; 
(1 manufacturing line, 2 change-overs) 
Traditional dry powder mixing, compressing in 
a batch process;  
(1 line + 1 change-over, flexible press); + 
assembly process 
Distribution: 3 SKU  76 SKU 
Use: User provided with a package of standard 
dosage of API 
User provided with a customised dosage of 
API 
End of life: Ideally return leftover doses to recycling/ 
waste treatment, Package to 
recycling/landfill 
Ideally no leftovers 
Package to recycling/landfill 
5.1.2 Qualitative sustainability performance comparison  
The qualitative comparison of results in Table 2 are as follows; in the raw material extraction and processing 
phase, the use of chemicals and solvents, the use of fossil energy and intensive water consumption are examples 
of issues for the TPC, and a decreased total demand of resources can be expected for the CPC (Slater et al., 
2013). In the social dimension, it is likely to encounter issues with work conditions for the TPC, and no change 
can be expected for the CPC. In the economic dimension, the TPC is associated with challenges concerning 
various costs for resources and operations, which are likely to decrease for the CPC as a result of a decreased 
total demand of resources (Slater and Savelski, 2007; Sheldon, 2016). A CPC, based on the assumption that a 
reduction in material processing is expected, may lead to a reduction of emissions, wastes and water 
consumption (Unger, 2013; Sheldon, 2016). The social dimension may be associated with workplace challenges 
in the form of risks for chemical exposure and repetitive work for the TPC (Segawa et al., 2016; Savoia et al., 
2017), and no change can be expected for the CPC. The economic dimension is associated with costs for 
material and operations for the TPC, and increased costs may be expected due to the need of investments in new 
technology and additional assembly process, and adjustment of information on packages. However, increased 
innovation capabilities due to the best available technology can be an opportunity. 
The distribution phase for the TPC is associated with fossil fuel use and emissions in ecological dimension, 
which are likely to increase for the CPC due to increased complexity as multiple variants are introduced (Srai et 
al., 2015). No difference can be expected between the TPC and CPC in the social dimension. The increased 
complexity may, however, induce increased costs for the CPC compared to the TPC in the economic dimension. 
In the use phase, no difference is expected in ecological performance. In the social dimension, the CPC 
inducing an increased treatment quality is expected (Savoia et al., 2017), but consequently an increased price 
compared to the TPC. In the economic dimension, an increased price can be problematic from a market 
attractiveness perspective (Nicholson Price and Rai, 2015).  
At the end of life phase, the TPC is associated with linked environmental challenges, including emissions of 
chemical substances to water and soil, as well as waste management practices of material packaging and 
surplus dosages (Srai et al., 2015). These challenges are all likely to be decreased for the CPC. In the social 
dimension, less risk for challenges associated with chemical exposure and societal costs for waste 
management is expected. The economic dimension is unlikely to change. 
5.2 Value chain impact analysis and value modelling 
Table 3 summarizes the results from the comparative sustainability assessment and the value chain impact 
analysis. For each value chain phase, respective VDIVs are listed and categorized according to SD, E-
ecological, S-social and $-economic. The CPC is compared to the TPC for each VDIV in each SD. If a VDIV 
increases, decreases or remains the same (or the change is unknown) with respect to value, the CPC scores a 
“+”,“-” or “0”, respectively. 
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Table 3. The VDIV for each value chain phase and the relative value change. 
Value chain phase Value driving impact variable TPC CPC 
 E $ S 
Secondary production Raw material consumption R + +  
Solvent consumption E 0 0  
Investments F  -  
Inventory E  +  
Delivery to 
dispensing point 
Transportation R - - + 
Packaging cost E  -  
Inventory N  +  
Dispensing to end 
user 
End-of-life waste C +   
Unit cost E  - - 
Administration effort    + 
Release properties    + 
Side effects    + 
The results in Table 3 are quantified and plotted for each scenario prepared in Table 1, see Figure 5. For 
scenarios emphasising social and ecological sustainability, i.e. Scenario 1 and 4, the preferred product design 
is the CPC. In Scenario 2, where the major emphasis is placed on the social dimension and the second major 
on the economic dimension, the CPC will still perform better than the TPC value-wise. 
6 DISCUSSION 
This study has proposed a methodology to conduct value assessments of medicinal products from a 
sustainability perspective. The selection of guiding questions by Villamil et al. (2018) for the sustainability 
lifecycle analysis brings difficulty in reproducing the study. The relevant guiding questions for the topic 
studied has been completely decided by previous experiences, literature, knowledge and interpretations of the 
researcher. Hence, SPVs describing the TPC and the CPC can be highly varied depending on the researcher 
performing the study. Future work should include comprehensive studies regarding the selection of the set of 
guiding questions for medicinal products. 
Overall, the proposed methodology is transferable to other products and performed by adapting the product 
platform to a desired product concept. The transferability to other ODFs, e.g. capsules or liquids, is conducted 
by adjusting the functioning bandwidths of product platform presented in Figure 4. The methodology can also 
be applied to medical devices, for instance, an insulin delivery device. An insulin delivery device would 
consist of insulin and a device providing the means of administering the insulin. The architecture of the 
insulin delivery device can be established by adjusting the architecture of tablet, see Figure 4. The treat 
disease FR on the second hierarchical level can be solved by the API system DS (referring to insulin in a 
realizable form). On the lowest hierarchical level, various types of insulin can be generated by introducing 
bandwidths to the DSs. Further, the provide suitable size FR can be generally expressed as provide convenient 
drug delivery, hence expanding the functional bandwidth beyond a tablet. Thus, the FR can be solved by the 
insulin delivery device DS and physically realized as various types of devices. Platform execution generates 
various insulin - insulin delivery device variants and the compatibility to patient attributes can be increased 
through medication adherence. The number of successful treatments can increase and the value of VDIVs in 
the social and economic SD. Poor adherence of diabetes medication has shown to be a major cost for health 
care due to for example hospitalisations (Ho et al., 2006). 
 
Figure 5. Relative value of CPC compared to TPC for each scenario prepared in table 1. 
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Revisiting the research question ‘How is the value chain affected from a sustainability perspective due to an 
introduction of customized product design?’ can be stated that in the value chain, value is created for 
scenarios emphasizing social and environmental sustainability. An introduction of a CPC leads to reduced 
API consumption and reduced side effects because of an elimination of surplus dosing. Surplus dosing with 
the TPC is an assumption and the API consumption can be overestimated. Excipient consumption 
decreases due to the scalability of the number of filling modules and constraining the maximum product 
volume of the CPC.  
A flexible size and shape are assumed to decrease administration effort and enhance release properties. The 
freedom of scaling the number of filling modules, covering the whole feasible product variant volume 
range, is considered a valid opportunity. The sizes of the TPC variants are the same regardless of dose 
content and hence, it is assumed that the API to excipient ratio is not optimized for the TPC. A traditional 
production process is assumed to remain the same but the adjustability of a tablet press to the considerably 
smaller module size of a CPC is not verified and need further investigation. Further, solvent consumption 
needs to be studied when elaborate studies on production processes are performed. 
The CPC is assumed to better match the medication demand, which entails a shift from a high to low 
inventory environment, both in the secondary production- and delivery phase. This shift increases value 
from an economic perspective. The unit cost of the CPC will increase, hence becoming less affordable and 
value destructive from a social perspective. 
Each VDIV in the value model is judged equally important within an SD. A comparison regarding the 
better or worse performance of the CPC to the TPC is provided but the magnitude is not given. Thus, scales 
to rate the VDIVs according to should be implemented.  
For the respective SDs, the VDIVs are judged equally important, e.g. the VDIV unit cost and reduction of 
side effects, in the social dimension, are both given the same absolute quantity. A patient might have a 
higher willingness to pay for a product eliminating side effects, which should be emphasized more. Thus, 
internal weightings should be introduced. 
7 CONCLUSIONS AND FUTURE WORK 
The proposed methodology shows that a value-driven approach can be used to support systematic decisions 
regarding medicinal product designs. The methodology adopts a full sustainability perspective and provides 
opportunities to study effects on the whole value chain of pharmaceutical products. However, conducting 
the sustainability performance assessment of product concepts is highly governed by researchers’ 
experiences, knowledge and available literature, hence complicating the reproducibility of the study. Future 
studies on sustainability performance criteria of medicinal products need to be conducted. Additionally, this 
method will be expanded in the future to enable the assessment of various new product concepts on more 
elaborate quantitative scales. Furthermore, internal weightings of VDIVs in respective sustainability 
dimension should be introduced to emphasise VDIVs considered to be more important. The proposed 
methodology can be transferred to products beyond the ODF, shown conceptually on a medical device.  
Data show that: A CPC is preferable if value is to be created from a social or/and an environmental 
sustainability perspective. 
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